Gastric lymphoma

Summary

Gastric lymphoma (MONDO:0001059) is a cancer. A subtype of gastric cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric lymphoma
Mondo ID	MONDO:0001059
DOID	DOID:10540
NCIT	C4636
SNOMED CT	276811008
UMLS	C0349532
MedGen	87603
GARD	0022871
NORD	1607
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: gastric lymphoma · lymphoma of stomach · lymphoma of the stomach · Primary Gastric Lymphoma · primary gastric lymphoma · stomach lymphoma

Disease family

This is a subtype of gastric cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › gastric lymphoma

Related subtypes (8): malignant gastric granular cell tumor, pylorus cancer, cardia cancer, malignant gastric germ cell tumor, gastric leiomyosarcoma, gastric liposarcoma, gastric carcinoma, diffuse gastric cancer

Subtypes (1): gastric non-hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.